Not intended for human use
This formula is sure to be of interest to researchers interested in enhanced injury recovery, as well as addressing symptoms of inflammatory, cardiovascular, and neurological diseases
Gene expression regulation, particularly in metabolic and enzymatic research models.Mitochondrial ATP production pathways, supporting metabolic efficiency and energy-related cellular studies
because rigorously controlled human safety data specific to the TB-500 fragment does not exist, its longer-term risk profile, including possible immune reactions, remains unknown Evidence snapshot: Evidence for TB-500 itself is preclinical, drawn mainly from cell-culture and animal studies (a 1999 rat wound-healing study and later rodent cardiac- and tendon-injury models), with a 2026 scoping review describing the musculoskeletal literature on thymosin beta-4 and TB-500 as sparse and largely preclinical
We are following guidance from the government and leading health policy organizations on how best to protect our team and patients from becoming infected and otherwise limit potential for disease transmission
Consistency with dosing during this establishment phase helps build the foundation for subsequent improvement